FDA approves Replimune melanoma drug previously rejected twice
The FDA has approved Replimune's melanoma drug after two previous rejections.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 7.
Source diversity sample: STAT · BioPharma Dive · qz.com · Endpoints News · Yahoo Finance · Reuters · Fierce Pharma · WSJ.
How this dossier is built: methodology · AI policy · corrections.
How fast it spread
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
What happened
The FDA has approved Replimune's melanoma drug TUDRIQEV in combination with Nivolumab for treating unresectable advanced cutaneous melanoma. The drug had been rejected twice previously. The drug is approved for patients who have progressed on an anti-PD-1 based regimen.
The FDA's decision follows a long regulatory battle. The Wall Street Journal notes that this is the third attempt at approval. The current state of the drug's approval is clear: it is now approved for the specified use.
No outlets contradict this.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 5h ago.
Sources (10)
- Pharmalittle: We're reading about Replimune's melanoma drug, a Medicare policy change, and more STAT · 18h ago
- Replimune rebounds to win FDA approval of melanoma drug BioPharma Dive · 18h ago
- FDA approves Replimune's Tudriqev melanoma drug on third try qz.com · 18h ago
- Replimune melanoma drug snags coveted FDA approval after yearlong clash, two rejections Endpoints News · 18h ago
- REPL Stock Slumps 11% After-Hours Yahoo Finance · 19h ago
- Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen Yahoo Finance · 19h ago
- US FDA approves Replimune's skin cancer drug after prior rejections Reuters · 19h ago
- Replimune secures FDA approval for melanoma therapy Tudriqev after long regulatory battle Fierce Pharma · 19h ago
- FDA Approves Replimune’s Melanoma Drug on Third Attempt WSJ · 19h ago
- FDA approves Replimune melanoma drug previously rejected twice STAT · 19h ago
Questions people are asking
What is the name of the approved drug?
The approved drug is TUDRIQEV.
What type of cancer does the drug treat?
The drug treats unresectable advanced cutaneous melanoma.
How many times was the drug previously rejected?
The drug was previously rejected twice.
Topics
Related trends
Food recalls keep growing. Eggs, lettuce, soup and more affected
Food recalls are expanding, affecting a wide range of products from eggs to soup.
1.5 million cartons of eggs have been recalled for Salmonella
A massive egg recall for Salmonella has affected 1.5 million cartons, with multiple states reporting hospitalizations.
Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments
Takeda's narcolepsy drug Orzeyful is the first of its kind to win FDA approval, opening a new chapter in sleep disorder treatment.
Cyclospora cases in Nebraska, Iowa linked to outbreak sourced to Taylor Farms lettuce
Cyclospora cases in Nebraska and Iowa are linked to a national outbreak traced to Taylor Farms lettuce.
F.D.A. Approves Moderna’s mRNA Flu Vaccine
The FDA has approved the first mRNA flu vaccine, a decade after the technology was first used in COVID-19 vaccines.
FDA approves 1st mRNA flu shot, from Moderna
The FDA has approved the first mRNA flu vaccine, marking a significant shift in flu shot technology.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.